2023-04-20 12:10:08 ET
- Kane Biotech ( OTCQB:KNBIF ) said it signed a distribution agreement with ProgenaCare Global for its coactiv+ Antimicrobial Wound Gel in the U.S. wound care market.
- ProgenaCare will have exclusive distribution rights in the U.S. for Kane's coactiv+ Antimicrobial Wound Gel and Kane will receive $500K upfront once it gets a 510(k) clearance from the U.S. Food and Drug Administration (FDA).
- "This is a defining milestone for Kane as we have secured a U.S. partner to bring our technologies to the wound care and surgical markets," said President and CEO Marc Edwards.
For further details see:
Kane grants distribution rights for wound gel to ProgenaCare in US